Algorithme Pharma Presents at Quebec Drug Development Symposium

During a recent drug development symposium held at the NEOMED Institute in Montreal, Dr. Marc Lefebvre, Vice-President Scientific & Regulatory Affairs, Algorithme Pharma Inc., addressed life science executives on developing efficient First-In-Human (FIH) clinical trials to help reduce costs and shorten the timeline for approval of new drugs.

(Laval, Quebec, Canada, March 26, 2014) – During a recent drug development symposium held at the NEOMED Institute in Montreal, Dr. Marc Lefebvre, Vice-President Scientific & Regulatory Affairs, Algorithme Pharma Inc., addressed life science executives on developing efficient First-In-Human (FIH) clinical trials to help reduce costs and shorten the timeline for approval of new drugs.

“When designing effective FIH trials, many factors need to be considered, such as quality of formulations, bioanalytical methods, study populations and safety assessment as these can have a significant project impact”, stated Dr. Marc Lefebvre.

Through local development partnerships, such as those fostered through the NEOMED Institute, local industry exchanges between public, private and academic institutions continue to help strengthen the scientific offering of our community.

For more information on this presentation, please visit http://www.youtube.com/user/AlgorithmePharma

About Algorithme Pharma
Algorithme Pharma, an Altasciences Company, is a full service provider focused on early stage clinical research. With over 20 years’ experience, Algorithme Pharma successfully completes more than 200 clinical trials annually. Support services include large and small molecule Bioanalysis, Data Management, Biostatistics, Regulatory Support, Clinical Pharmacology and Project Management.

Information:

Algorithme Pharma
Catherine Konidas
Vice-President, Global Business Development
Tel.: 450-973-6077
ckonidas@algopharm.com | www.algopharm.com